{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:43:21Z","timestamp":1792633401132,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.amjcard.2025.02.034","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T11:29:57Z","timestamp":1741260597000},"page":"42-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Lipoprotein(a) \u2013 From Biomarker to Therapy: A Review for the Clinician"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-0349","authenticated-orcid":false,"given":"Mawra","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbar R.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-4051","authenticated-orcid":false,"given":"Eli V.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.amjcard.2025.02.034_bib0001","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.amjcard.2025.02.034_bib0002","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0003","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0004","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0021-9150(03)00143-6","article-title":"Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease","volume":"169","author":"Geethanjali","year":"2003","journal-title":"Atherosclerosis"},{"issue":"1-2","key":"10.1016\/j.amjcard.2025.02.034_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0021-9150(81)90103-9","article-title":"Lipoprotein Lp(a) and the risk for myocardial infarction","volume":"38","author":"Kostner","year":"1981","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0008","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0009","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"19","key":"10.1016\/j.amjcard.2025.02.034_bib0011","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1016\/S0021-9258(19)84439-3","article-title":"Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a)","volume":"261","author":"Fless","year":"1986","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-2275(20)38724-1","article-title":"Isolation and characterization of the two major apoproteins in human lipoprotein [a]","volume":"28","author":"Gaubatz","year":"1987","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0013","first-page":"459","article-title":"Characterization of the Lp(a) lipoprotein in human plasma","volume":"78","author":"Simons","year":"1970","journal-title":"Acta Pathol Microbiol Scand [B] Microbiol Immunol"},{"issue":"7","key":"10.1016\/j.amjcard.2025.02.034_bib0014","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/hmg\/2.7.933","article-title":"Molecular definition of the extreme size polymorphism in apolipoprotein(a)","volume":"2","author":"Lackner","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.amjcard.2025.02.034_bib0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00201550","article-title":"Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups","volume":"86","author":"Sandholzer","year":"1991","journal-title":"Hum Genet"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0016","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00041433-199904000-00007","article-title":"Genetic architecture and evolution of the lipoprotein(a) trait","volume":"10","author":"Utermann","year":"1999","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.amjcard.2025.02.034_bib0017","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","article-title":"Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease","volume":"16","author":"Kraft","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0018","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"van der Hoek","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.amjcard.2025.02.034_bib0019","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.jlr.2023.100336","article-title":"Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort","volume":"64","author":"Matveyenko","year":"2023","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0020","article-title":"Role of Lipoprotein (A) in aortic valve stenosis: novel disease mechanisms and emerging pharmacotherapeutic approaches","volume":"55","author":"Khan","year":"2024","journal-title":"IJC Heart Vasc"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/923289","article-title":"Lipoprotein(a): cellular effects and molecular mechanisms","volume":"2012","author":"Riches","year":"2012","journal-title":"Cholesterol"},{"issue":"9","key":"10.1016\/j.amjcard.2025.02.034_bib0022","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI119753","article-title":"The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor","volume":"100","author":"Argraves","year":"1997","journal-title":"J Clin Invest"},{"issue":"6222","key":"10.1016\/j.amjcard.2025.02.034_bib0023","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/339303a0","article-title":"Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis","volume":"339","author":"Hajjar","year":"1989","journal-title":"Nature"},{"issue":"39","key":"10.1016\/j.amjcard.2025.02.034_bib0024","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.amjcard.2025.02.034_bib0025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation","volume":"169","author":"Derby","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.amjcard.2025.02.034_bib0026","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1194\/jlr.P084517","article-title":"Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women\u2019s Interagency HIV Study","volume":"59","author":"Enkhmaa","year":"2018","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.amjcard.2025.02.034_bib0027","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/nu12072024","article-title":"Diet and Lp(a): does dietary change modify residual cardiovascular risk conferred by Lp(a)?","volume":"12","author":"Enkhmaa","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0028","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ajcn\/nqab287","article-title":"Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial","volume":"115","author":"Ebbeling","year":"2022","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.amjcard.2025.02.034_bib0030","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.amjcard.2025.02.034_bib0031","doi-asserted-by":"crossref","first-page":"dgaa672","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6826","key":"10.1016\/j.amjcard.2025.02.034_bib0032","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/bmj.304.6826.545","article-title":"Lipoprotein(a) in cirrhosis","volume":"304","author":"Feely","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/480784","article-title":"Systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis","volume":"2012","author":"Missala","year":"2012","journal-title":"Int J Rheumatol"},{"issue":"18","key":"10.1016\/j.amjcard.2025.02.034_bib0034","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","article-title":"Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women","volume":"279","author":"Walsh","year":"1998","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0035","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1523-1755.2004.00418.x","article-title":"The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome","volume":"65","author":"Kronenberg","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0036","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J Am Soc Nephrol JASN"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0037","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J Am Soc Nephrol JASN"},{"issue":"6","key":"10.1016\/j.amjcard.2025.02.034_bib0038","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjcard.2025.02.034_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030651","article-title":"Levels of Lipoprotein (a) in patients with coronary artery disease with and without inflammatory rheumatic disease: a cross-sectional study","volume":"9","author":"Holm","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/ATVBAHA.112.300125","article-title":"HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels","volume":"33","author":"Enkhmaa","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0041","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.scitotenv.2018.11.149","article-title":"Associations between Fine Particulate Matter and Changes in Lipids\/Lipoproteins among Midlife Women","volume":"654","author":"Wu","year":"2019","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.07.020","article-title":"Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease","volume":"308","author":"Jung","year":"2020","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0043","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/01.ATV.13.2.296","article-title":"Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations","volume":"13","author":"Ed\u00e9n","year":"1993","journal-title":"Arterioscler Thromb J Vasc Biol"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0044","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0026-0495(86)90150-2","article-title":"Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum","volume":"35","author":"Zechner","year":"1986","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0045","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(99)00296-8","article-title":"Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia","volume":"148","author":"Sattar","year":"2000","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0046","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1172\/JCI115699","article-title":"Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma","volume":"89","author":"Henriksson","year":"1992","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.amjcard.2025.02.034_bib0047","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","article-title":"Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women","volume":"8","author":"Salpeter","year":"2006","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0048","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.20.4.1137","article-title":"Major reduction in plasma Lp(a) levels during sepsis and burns","volume":"20","author":"Mooser","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.amjcard.2025.02.034_bib0049","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.amjcard.2025.02.034_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100239","article-title":"Development and validation of an isoform-independent monoclonal antibody\u2013based ELISA for measurement of lipoprotein(a)","volume":"63","author":"Marcovina","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0052","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0053","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0054","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.amjcard.2025.02.034_bib0056","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and Cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.amjcard.2025.02.034_bib0057","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017470","article-title":"Lipoprotein(a) and Coronary Artery Disease Risk Without a Family History of Heart Disease","volume":"10","author":"Finneran","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.amjcard.2025.02.034_bib0058","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.amjcard.2025.02.034_bib0059","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"INTERHEART Investigators. Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016604","article-title":"Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey","volume":"6","author":"Dumitrescu","year":"2011","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0061","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.ATV.8.4.398","article-title":"Lipoprotein Lp(a). A risk factor for myocardial infarction","volume":"8","author":"Hoefler","year":"1988","journal-title":"Arterioscler Dallas Tex"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.R071571","article-title":"Lipoprotein (a): a historical appraisal","volume":"58","author":"Kostner","year":"2017","journal-title":"J Lipid Res"},{"issue":"10","key":"10.1016\/j.amjcard.2025.02.034_bib0063","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease. A study in six populations","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arterioscler Thromb J Vasc Biol"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0064","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/clinchem\/36.1.20","article-title":"Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age","volume":"36","author":"Sandkamp","year":"1990","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0065","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0735-1097(92)90520-W","article-title":"Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease","volume":"19","author":"Genest","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.amjcard.2025.02.034_bib0066","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.1993.03510180065035","article-title":"A prospective study of lipoprotein(a) and the risk of myocardial infarction","volume":"270","author":"Ridker","year":"1993","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.amjcard.2025.02.034_bib0067","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1373\/clinchem.2003.030031","article-title":"Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians\u2019 Health Study","volume":"50","author":"Rifai","year":"2004","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.amjcard.2025.02.034_bib0068","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.amjcard.2025.02.034_bib0069","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"issue":"9","key":"10.1016\/j.amjcard.2025.02.034_bib0070","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"issue":"26","key":"10.1016\/j.amjcard.2025.02.034_bib0071","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjcard.2025.02.034_bib0072","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0073","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/joim.12335","article-title":"Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia","volume":"278","author":"Vongpromek","year":"2015","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.amjcard.2025.02.034_bib0074","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in Caucasian and Black individuals: The Multi-Ethnic Study of Atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.amjcard.2025.02.034_bib0075","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","article-title":"Causal effect of Lp(a) [Lipoprotein(a)] level on ischemic stroke and Alzheimer disease","volume":"50","author":"Pan","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0076","doi-asserted-by":"crossref","unstructured":"Aronis KN, Zhao D, Hoogeveen RC, Alonso A, Ballantyne CM, Guallar E, Jones SR, Martin SS, Nazarian S, Steffen BT, Virani SS, Michos ED. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 6(12):e007372. 10.1161\/JAHA.117.007372","DOI":"10.1161\/JAHA.117.007372"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0077","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149427","article-title":"Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism","volume":"11","author":"Sticchi","year":"2016","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.amjcard.2025.02.034_bib0078","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.amjcard.2025.02.034_bib0079","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1161\/01.CIR.100.11.1154","article-title":"Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study","volume":"100","author":"Kronenberg","year":"1999","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjcard.2025.02.034_bib0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF02002128","article-title":"Lipoprotein(a): a risk factor for peripheral vascular disease","volume":"7","author":"Widmann","year":"1993","journal-title":"Ann Vasc Surg"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0081","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1078-5884(97)80220-1","article-title":"Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease","volume":"14","author":"Cheng","year":"1997","journal-title":"Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg"},{"issue":"12","key":"10.1016\/j.amjcard.2025.02.034_bib0082","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0083","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2023.04.017","article-title":"Role of Lipoprotein A in Lower Extremity Peripheral Artery Disease","volume":"198","author":"Banerjee","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0084","unstructured":"Lipoprotein(a) in Clinical Practice. American College of Cardiology. Accessed June 23, 2024. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2019\/07\/02\/08\/05\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2019%2f07%2f02%2f08%2f05%2fLipoproteina-in-Clinical-Practice"},{"issue":"18","key":"10.1016\/j.amjcard.2025.02.034_bib0085","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.amjcard.2025.02.034_bib0086","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","volume":"101","author":"Langsted","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0087","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/gepi.22360","article-title":"eMERGE Consortium, Jarvik GP. Loci identified by a genome-wide association study of carotid artery stenosis in the eMERGE network","volume":"45","author":"Palmer","year":"2021","journal-title":"Genet Epidemiol"},{"issue":"33","key":"10.1016\/j.amjcard.2025.02.034_bib0088","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0089","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0090","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.amjcard.2025.02.034_bib0091","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0092","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0129","article-title":"Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Disease-Free Survival, and Mortality Risk: A Mendelian Randomization Analysis","volume":"3","author":"Arsenault","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.amjcard.2025.02.034_bib0093","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1055\/a-1340-2109","article-title":"Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study","volume":"121","author":"Cao","year":"2021","journal-title":"Thromb Haemost"},{"issue":"3-4","key":"10.1016\/j.amjcard.2025.02.034_bib0094","first-page":"143","article-title":"Lipoprotein (a) and risk of cardiovascular disease\u2013a systematic review and meta analysis of prospective studies","volume":"57","author":"Genser","year":"2011","journal-title":"Clin Lab"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.amjcard.2025.02.034_bib0096","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.amjcard.2025.02.034_bib0097","first-page":"e1046","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.amjcard.2025.02.034_bib0098","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.amjcard.2025.02.034_bib0099","first-page":"1196","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"25","key":"10.1016\/j.amjcard.2025.02.034_bib0100","first-page":"e1046","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.amjcard.2025.02.034_bib0101","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMe1202168","article-title":"Lowering plasma cholesterol by raising LDL receptors\u2014revisited","volume":"366","author":"Young","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjcard.2025.02.034_bib0102","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0011-393X(05)80318-2","article-title":"Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemia","volume":"55","author":"Avellone","year":"1994","journal-title":"Curr Ther Res"},{"issue":"10155","key":"10.1016\/j.amjcard.2025.02.034_bib0103","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"24","key":"10.1016\/j.amjcard.2025.02.034_bib0104","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0105","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s40001-023-01155-x","article-title":"Association of statin use and increase in lipoprotein(a): a real-world database research","volume":"28","author":"Feng","year":"2023","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0106","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12872-022-02932-y","article-title":"Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease","volume":"22","author":"hu","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.amjcard.2025.02.034_bib0107","doi-asserted-by":"crossref","first-page":"17887","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.amjcard.2025.02.034_bib0108","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.amjcard.2025.02.034_bib0109","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjcard.2025.02.034_bib0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.amjcard.2025.02.034_bib0111","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1139\/cjpp-2014-0478","article-title":"Niacin as antidyslipidemic drug","volume":"93","author":"Julius","year":"2015","journal-title":"Can J Physiol Pharmacol"},{"issue":"9","key":"10.1016\/j.amjcard.2025.02.034_bib0112","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering lipoprotein (a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.amjcard.2025.02.034_bib0113","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0114","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12916-017-0787-7","article-title":"Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials","volume":"15","author":"Sahebkar","year":"2017","journal-title":"BMC Med"},{"issue":"17","key":"10.1016\/j.amjcard.2025.02.034_bib0115","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0116","series-title":"Endotext","article-title":"Lipoprotein Apheresis","author":"Feingold","year":"2000"},{"issue":"9","key":"10.1016\/j.amjcard.2025.02.034_bib0117","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Pro(a)LiFe-Study Group. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8_Supplement","key":"10.1016\/j.amjcard.2025.02.034_bib0118","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/S0735-1097(23)03757-9","article-title":"Niacin treatment effective for reducing lp(a) levels","volume":"81","author":"Echeverry","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.amjcard.2025.02.034_bib0119","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.amjcard.2025.02.034_bib0120","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","article-title":"null null. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering","volume":"84","author":"O \u2019Donoghue Michelle","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.amjcard.2025.02.034_bib0121","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.amjcard.2025.02.034_bib0122","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.amjcard.2025.02.034_bib0123","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11883-023-01141-y","article-title":"Treatment of Lp(a): is it the future or are we ready today?","volume":"25","author":"Tselepis","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"16","key":"10.1016\/j.amjcard.2025.02.034_bib0124","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC Focus Seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.amjcard.2025.02.034_bib0125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjcard.2025.02.034_bib0126","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2025.02.034_bib0127","series-title":"A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of olpasiran on major cardiovascular events in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a)","year":"2024"},{"issue":"12","key":"10.1016\/j.amjcard.2025.02.034_bib0128","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.amjcard.2025.02.034_bib0129","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.amjcard.2025.02.034_bib0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/qjmed\/93.2.75","article-title":"Lipoprotein(a): from ancestral benefit to modern pathogen?","volume":"93","author":"Lippi","year":"2000","journal-title":"QJM Int J Med"},{"issue":"10","key":"10.1016\/j.amjcard.2025.02.034_bib0131","first-page":"1050","article-title":"Impact of high lipoprotein(a) levels on delayed wound healing in patients with chronic limb-threatening ischemia after peripheral endovascular therapy","volume":"88","author":"Tomoi","year":"2024","journal-title":"Circulation Journal"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925001201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925001201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:24:34Z","timestamp":1777695874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":131,"alternative-id":["S0002914925001201"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.02.034","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) \u2013 From Biomarker to Therapy: A Review for the Clinician","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.02.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}